In-vitro permeation of bevacizumab through human sclera: Effect of iontophoresis application

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 9, 2010, Pages 1189-1194

  Pescina, Silvia ^a   Ferrari, Giulio ^a   Govoni, Paolo ^a   MacAluso, Claudio ^a   Padula, Cristina ^a   Santi, Patrizia ^a   Nicoli, Sara ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

bevacizumab; fluorescein isothiocyanate; iontophoresis; transscleral permeation

Indexed keywords

BEVACIZUMAB; FLUORESCEIN ISOTHIOCYANATE;

ARTICLE; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG STABILITY; DRUG TRANSPORT; HUMAN; HUMAN TISSUE; IONTOPHORESIS; RETINA MACULA AGE RELATED DEGENERATION; SCLERA; THIN LAYER CHROMATOGRAPHY; ZETA POTENTIAL;

ABSORPTION; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; DIFFUSION; DRUG DELIVERY SYSTEMS; FLUORESCENCE; HUMANS; IONTOPHORESIS; SCLERA;

EID: 77955242157     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01153.x     Document Type: Article

References (28)

1. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 2006 58 : 686 706.
2. FDA (2004). Avastin (bevacizumab). US Food and Drug Administration: Silver Spring, MD. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2004/STN- 125085-Avastin.cfm (accessed 28 June 2010).
3. Sharif NA, Klimko P. Ophtalmic agents. In : Triggle D, Taylor J, eds. Comprehensive Medicinal Chemistry II, vol 6. Oxford : Elsevier, 2006 : 297 320.
4. Ambati J et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci 2000 41 : 1181 1185.
5. Jarvinen K et al. Ocular absorption following topical delivery. Adv Drug Deliv Rev 1995 16 : 3 19.
6. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006 58 : 1131 1135.
7. Jiang J et al. Intrascleral drug delivery to the eye using hollow microneedles. Pharm Res 2009 26 : 395 403.
8. Jiang J et al. Coated microneedles for drug delivery to the eye. Invest Ophthalmol Vis Sci 2007 48 : 4038 4043.
9. Kalia YN et al. Iontophoretic drug delivery. Adv Drug Deliv Rev 2004 56 : 619 658.
10. Li YZ et al. Trypsin as a novel potential absorption enhancer for improving the transdermal delivery of macromolecules. J Pharm Pharmacol 2009 61 : 1005 1012.
11. Watson PG, Young RD. Scleral structure, organisation and disease. A review. Exp Eye Res 2004 78 : 609 623.
12. Parkinson TM et al. Tolerance of ocular iontophoresis in healthy volunteers. J Ocul Pharmacol Ther 2003 19 : 145 151.
13. Nicoli S et al. Porcine sclera as a model of human sclera for in vitro transport experiments: histology, SEM, and comparative permeability. Mol Vis 2009 15 : 259 266.
14. Olsen TW et al. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci 1995 36 : 1893 1903.
15. Brinkley M. A brief survey of methods for preparing protein conjugates with dyes, haptens, and cross-linking reagents. Bioconjug Chem 1992 3 : 2 13.
16. The TH, Feltkamp TE. Conjugation of fluorescein isothiocyanate to antibodies. I. Experiments on the conditions of conjugation. Immunology 1970 18 : 865 873.
17. Wood BT et al. Fluorescent antibody staining. 3. Preparation of fluorescein-isothiocyanate-labeled antibodies. J Immunol 1965 95 : 225 229.
18. McKinney RM et al. A simple method for determining the labeling efficiency of fluorescein isothiocyanate products. Anal Biochem 1966 14 : 421 428.
19. Mahler HC et al. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm 2005 59 : 407 417.
20. Nobbmann U et al. Dynamic light scattering as a relative tool for assessing the molecular integrity and stability of monoclonal antibodies. Biotechnol Genet Eng Rev 2007 24 : 117 128.
21. Nicoli S et al. In vitro transscleral iontophoresis of high molecular weight neutral compounds. Eur J Pharm Sci 2009 36 : 486 492.
22. Li SK et al. Influence of asymmetric donor-receiver ion concentration upon transscleral iontophoretic transport. J Pharm Sci 2005 94 : 847 860.
23. Pikal MJ. The role of electroosmotic flow in transdermal iontophoresis. Adv Drug Deliv Rev 2001 46 : 281 305.
24. Eljarrat-Binstock E, Domb AJ. Iontophoresis: a non-invasive ocular drug delivery. J Control Release 2006 110 : 479 489.
25. Eyegate Pharma. http://www.eyegatepharma.com (accessed 10 March 2010).
26. Avery RL et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006 113: 1695 : e1 e15.
27. Kim SH et al. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res 2007 39 : 244 254.
28. Robinson MR et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res 2006 82 : 479 487.